Nicox has entered into an exclusive development and commercialization license agreement with Ocumension Therapeutics for Zerviate, Nicox’s allergic conjunctivitis treatment, according to a press release.
Under the terms of the agreement, Nicox may receive up to 17 million euros in milestone payments, plus royalties between 5% and 9%, and Ocumension will receive exclusive development and commercialization rights in China, Hong Kong, Macau and Taiwan for Zerviate (cetirizine ophthalmic solution 0.24%).
“Zerviate brings Ocumension an additional late-stage opportunity and expands our
Uncategorized